Table 5. Side effects from methotrexate treatmenta.
|
First course of treatment |
Subsequent courses |
|||
|---|---|---|---|---|
| Side effect | Grade I/II | Grade III/IV | Grade I/II | Grade III/IV |
| Anaemia | 2 (0.8%) | |||
| Neutropenia | 1 (0.4%) | 1 (0.4%) | 2 (0.8%) | |
| Thrombocytopenia | 1 (0.4%) | 1 (0.4%) | 1 (0.4%) | |
| Nausea | 19 (7.6%) | 37 (14.8) | ||
| Vomiting | 5 (2%) | 12 (4.8%) | ||
| Abdominal pain | 21 (8.4%) | 2 (0.8%) | 34 (1.6%) | 1 (0.4%) |
| Abnormal liver function | 1 (0.4%) | 1 (0.4%) | 3 (1.2%) | |
| Mucositis/stomatitis | 61 (24.4%) | 1 (0.4%) | 65 (26%) | 2 (0.8%) |
| Sore/bleeding gums | 2 (1.6%) | 8 (3.2%) | ||
| Epistaxis | 6 (2.4%) | 3 (1.2%) | ||
| Blepharitis/conjunctivitis | 61 (24.4%) | 60 (24%) | ||
| Pleuritic chest pain | 22 (8.8%) | 60 (24%) | 3 (1.2%) | |
| Shortness of breath | 1 (0.4%) | 5 (2%) | ||
| Pleural effusion | 1 (0.4%) | |||
| Skin rash | 8 (3.2%) | 1 (0.4%) | 2 (0.8%) | 1 (0.4%) |
| Vaginal bleeding | 49 (19.6%) | 4 (1.6%) | 38 (15.2%) | 2 (0.8%) |
a
In all, 92 (36.8%) had no toxicity during their first course; 67 (26.8%) had no toxicity during subsequent courses.